Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.

Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904.

View in: PubMed

subject areas

Adult
Aged
Antiviral Agents
Drug Therapy, Combination
Female
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Male
Middle Aged
Polyethylene Glycols
Recombinant Proteins
Research Design
Ribavirin
RNA, Viral
Sample Size
Treatment Failure
Treatment Outcome

authors with profiles

Donald M. Jensen